SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
Zacks·16h ago
More News
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
Zacks·6d ago
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.
Stocktwits·6d ago
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi PR Newswire CHICAGO, Oct. 16, 2025 CHICAGO...
PR Newswire·7d ago
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Zacks·7d ago
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Zacks·10d ago
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Zacks·10d ago
Top Research Reports for Walmart, Sony & Citigroup
Today's Research Daily features new research reports on 16 major stocks, including Walmart, Sony, and Citigroup, as well as a micro-cap stock, AgEagle.
Zacks·12d ago
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.
Zacks·14d ago
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.